DDInter424 DDInter782
Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Cobicistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Cobicistat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprazolam
Cobicistat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pitolisant
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Cobicistat {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Donepezil
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Doravirine
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cobicistat may lead to a major life threatening interaction when taken with Methylprednisolone
Cobicistat may lead to a major life threatening interaction when taken with Berotralstat